Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > $Value to Insiders from a Potential Buyout

<< Previous

Bullboard Posts

Next >>

Post by Probosciseson Jan 10, 2023 6:15pm

484 Views

Post# 35214565

$Value to Insiders from a Potential Buyout

I created an excel spreadsheet that calculates the value of the ONC/Y insiders' current shares and options at any buyout price or any additional ATM shares that I choose to include. The number of shares and options I got from SEDI and I have already presented these. The average exercise price of the options I estimate after looking a bit more closely at the SEDI data at between $2-$3 per share. If you want to be conservative use a $3 exercise price per share, multiply that by the number of options, and subtract that total from the total value of the shares and options to get the net value.

The number of fully diluted shares (which includes options) was given as of September 2022 as 64,388,508 shares. It is unknown how many more shares will be added by the ATM prior to a buyout. I can put whatever number I want for fully diluted shares into my spreadsheet. I can also play with whatever number I want for a buyout price. In this example I estimated 5,000,000 more ATM shares (so a total of 69,388,508 shares). For a buyout price I used $2,000,000 USD, but I've also played with scenarios of $4,000,000 - $8,000,000.

My results for a scenario of a buyout price of $2,000,000 USD, a total of 69,388,508 shares, and no recognition of the options exercise price (you can do that yourself) is as follows:

Gross income (in USD) to insiders from a sale of all their current shares and options at a buyout price of $2,000,000 USD:

MANAGEMENT
Matt Coffey. $41,821,000
Kirk Look. $24,796,000
Thomas Heineman. $12,566,000
Andrew de Guttadauro. $16,529,000
Allison Hagerman. $14,754,000

BOD
Wayne Pisano. $7,879,000
Deborah Brown. $3,292,000
Bernd Seizinger. $10,956,000
Angela Holtham. $5,462,000
James Parsons. $1,297,000
Johnathan Rigby. $1,297,000

If you are comfortable with spreadsheets you can make your own spreadsheet and play with whatever scenarios you want. Or you can take my numbers and multiply by whatever factor you want to compute the gross income at whatever buyout price you choose.